Bevacizumab and Vasoconstriction (BVZ1)
Rationale: The introduction of angiogenesis inhibitors has remarkably improved treatment of patients with several types of cancer. One of the most common side effects of angiogenesis inhibitors is hypertension. In patients treated with bevacizumab hypertension had an overall incidence up to 32%. The etiology of hypertension caused by treatment with angiogenesis inhibitors is unclear.
Objective: To study if arterial bevacizumab infusion causes acute vasoconstriction using plethysmography in healthy volunteers.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Bevacizumab and Vasoconstriction|
- Fore-arm vasomotor response to administered bevacizumab, expressed as percentage change in forearm blood flow ratio [ Time Frame: Infusion of bevacizumab during 6 minutes ] [ Designated as safety issue: No ]
- Correlation between VEGF concentrations in plasma and the vasoconstrictive response to bevacizumab [ Time Frame: Infusion of bevacizumab during 6 minutes ] [ Designated as safety issue: No ]
|Study Start Date:||June 2009|
|Study Completion Date:||November 2009|
|Primary Completion Date:||November 2009 (Final data collection date for primary outcome measure)|
Intra-arterial infusion during 6 minutes
Please refer to this study by its ClinicalTrials.gov identifier: NCT00929058
|Radboud University Nijmegen Medical Centre|
|Nijmegen, Netherlands, 6500|
|Principal Investigator:||Gerard Rongen, MD PhD||UMCN|